D-0377-2021 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0377-2021 was initiated by Teva Pharmaceuticals USA on Apr 26, 2021 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Jun 4, 2024). Affected quantity: 3,138/25 single use vials per tray.

Recall details

Product Type
Drugs
Report Date
May 26, 2021
Initiation Date
Apr 26, 2021
Termination Date
Jun 4, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3,138/25 single use vials per tray

Product description

Metoclopramide Injection USP, 10 mg/2 mL (5 mg/mL), 2 mL Single-Use Vial, Rx Only, TEVA Parenteral Medicines, Inc. Irvine, CA 92618 NDC 0703-4502-04

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

Product was distributed nationwide.

Code information

Lot # 31325459B, exp. date 08/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0377-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0377-2021. Report a data issue: hello@regdatalab.com.